Circulating Cytokeratin 18 Fragment M65—A Potential Marker of Malignancy in Colorectal Cancer Patients
Christoph Ausch(Ludwig Boltzmann Institute for Cardiovascular Research), Gerhard Hamilton(Medical University of Vienna), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Ulrike Olszewski(Ludwig Boltzmann Institute for Cardiovascular Research), E Ogris(Ludwig Boltzmann Institute for Cardiovascular Research), W Hinterberger(Ludwig Boltzmann Institute for Cardiovascular Research), R Schiessel(Ludwig Boltzmann Institute for Cardiovascular Research)
Cited by 33
Related Papers
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
|Blood|2011|448
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
|The Lancet Haematology|2020|351
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
|Blood Cancer Journal|2015|273